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Cellular/Molecular
miR126-5p Downregulation Facilitates Axon Degeneration
and NMJ Disruption via a Non–Cell-Autonomous
Mechanism in ALS
XRoyMaimon,1* Ariel Ionescu,1* Avichai Bonnie,1 Sahar Sweetat,2 ShaneWald-Altman,3 Shani Inbar,3 Tal Gradus,1
XDavide Trotti,4Miguel Weil,3 XOded Behar,2 and XEran Perlson1
1Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel, 2Department of Developmental
Biology and Cancer Research, Hebrew University of Jerusalem, Jerusalem 9190401 Israel, 3Department of Cell Research and Immunology, Tel Aviv
University, Tel Aviv 69978, Israel, and 4JeffersonWeinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience,
Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Axon degeneration and disruption of neuromuscular junctions (NMJs) are key events in amyotrophic lateral sclerosis (ALS) pathology.
Although the disease’s etiology is not fully understood, it is thought to involve a non–cell-autonomous mechanism and alterations in
RNA metabolism. Here, we identified reduced levels of miR126-5p in presymptomatic ALS male mice models, and an increase in its
targets: axon destabilizing Type 3 Semaphorins and their coreceptor Neuropilins. Using compartmentalized in vitro cocultures, we
demonstrated that myocytes expressing diverse ALS-causing mutations promote axon degeneration and NMJ dysfunction, which were
inhibited by applying Neuropilin1 blocking antibody. Finally, overexpressing miR126-5p is sufficient to transiently rescue axon degen-
eration and NMJ disruption both in vitro and in vivo. Thus, we demonstrate a novel mechanism underlying ALS pathology, in which
alterations in miR126-5p facilitate a non–cell-autonomous mechanism of motor neuron degeneration in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative
disease that affects motor neurons (MNs) in the cortex, brains-
tem, and spinal cord (SC) (Mulder et al., 1986; Peters et al., 2015).
It is characterized by neuromuscular junction (NMJ) disruption,
MN axon degeneration, and neuronal death (Frey et al., 2000;
Fischer et al., 2004; Moloney et al., 2014). Despite some progress,
currently no effective treatment is available for ALS. The diversity
of ALS-related mutations has given rise to the use of numerous
animal models with diverse phenotypes, ranging from no effect
on MN function to severe progressive paralysis (Philips and
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Significance Statement
Despite some progress, currently no effective treatment is available for amyotrophic lateral sclerosis (ALS). We suggest a novel
regulatory role for miR126-5p in ALS and demonstrate, for the first time, a mechanism by which alterations in miR126-5p
contribute to axon degeneration andNMJ disruption observed in ALS.We show thatmiR126-5p is altered in ALSmodels and that
it can modulate Sema3 and NRP protein expression. Furthermore, NRP1 elevations in motor neurons and muscle secretion of
Sema3A contribute to axon degeneration and NMJ disruption in ALS. Finally, overexpressing miR126-5p is sufficient to tran-
siently rescue NMJ disruption and axon degeneration both in vitro and in vivo.
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Rothstein, 2015). Approximately 20% of familial ALS is ac-
counted for by mutations in the superoxide dismutase 1 (SOD1)
gene (Scrutton et al., 1992; Rosen et al., 1993;Gurney et al., 1994).
Mutations in the SOD1 gene (mSOD1) have also been described
in sporadic cases (sALS) (Rakhit et al., 2004). Other mutations
found in ALS patients include hexanucleotide expansion repeats
in theC9orf72 locus, which lead to various dipeptide repeats (e.g.,
proline-arginine or glycine-arginine repeats: PR50 and GR50, re-
spectively), and in the gene encoding the TDP43 RNA binding
protein (Buratti, 2015; Wen et al., 2017). An efficient method for
studying NMJ stability and health in vitro is by using the micro-
fluidic chamber (MFC) system, which allows the culture of pri-
mary myocytes in one compartment, andMNs in the other, thus
setting up conditions conducive to generating active NMJs (Za-
havi et al., 2015).
The neurodegeneration that occurs in ALS is considered to be
a non–cell-autonomous process involving interactions between
the neuron and its diverse extracellular microenvironments via
an unknown mechanism (Ilieva et al., 2009; Tsitkanou et al.,
2016). Although the molecular basis for neuronal dysfunction
and death in ALS is still poorly understood, it may be due to
alterations in the nature of the extracellular signaling pathways
that switch fromprosurvival to toxic (Ilieva et al., 2009; Perlson et
al., 2009). Numerous studies support the notion that multiple
tissues outside the CNS, including skeletal muscle (Dupuis et al.,
2006; Tsitkanou et al., 2016), astrocytes (Nagai et al., 2007), and
microglia (Lee et al., 2016), contribute to ALS pathologies. Alter-
ations in RNA metabolism and microRNAs (miRs) can contrib-
ute to, and also be part of, mechanisms that initiate the disease
(Lemmens et al., 2010; Emde and Hornstein, 2014). miRs are
post-transcriptional regulators that play an important role in
many cellular processes, such as axon growth and retraction, and
were demonstrated to be involved in many diseases, including
neurodegenerative diseases, such as ALS (Hawley et al., 2017;
Molasy et al., 2017). Alterations in miR expression profile were
identified specifically in axons of ALS models (Rotem et al.,
2017), as well in muscles leading to increasing attempts to either
use or targetmiRs as therapeutic strategies (Di Pietro et al., 2017).
Therefore, it is reasonable to assume that alterations in RNA and
miRNA metabolism, of both MNs and neighboring cells, can
regulate a secreted destabilizing signal, which in turn, facilitates
axon degeneration and NMJ disruption.
Semaphorin3A (Sema3A)was initially identified as a repellent
guidance molecule (Luo et al., 1993; Worzfeld and Offermanns,
2014). However, later works showed that it can also induce neu-
ronal cell death of sympathetic, sensory, retinal, and cortical neu-
rons (Nakamura et al., 2000; Shirvan et al., 2002; Ben-Zvi et al.,
2008; Jiang et al., 2010). Neuropilin1 (NRP1) has been shown to
be the receptor binding component for Sema3A as well as some
other Type 3 Semaphorins (Kolodkin et al., 1997). Sema3A was
found to be upregulated followingCNS injury as well as in several
neurodegenerative diseases (Kaneko et al., 2006; Van Battum et
al., 2015). Importantly, Sema3A was found to be upregulated in
terminal Schwann cells of the SOD1G93A transgenicmousemodel
for ALS and in themotor cortex of ALS patients (DeWinter et al.,
2006; Ko¨rner et al., 2016), suggesting that it plays a toxic role in
disease pathology and progression.
Here we demonstrated that alterations in miR126-5p result
in upregulation of Type 3 Semaphorins and its cobinding receptor
NRP1 in muscles and MN axons of ALS models, respectively. We
further demonstrate in vitro and in vivo the contribution of this
pathway to axon degeneration and NMJ disruption in ALSmodels.
Materials andMethods
Animals and vector injections.HB9::GFP (stock #005029)mice were orig-
inally obtained from The Jackson Laboratory. The colony was main-
tained by breeding with ICRmice. SOD1G93A (stock #002726) mice were
originally obtained from The Jackson Laboratory and maintained by
breedingwith C57BL/6Jmice. Genotypingwas performed using the PCR
(KAPA Biosystems); DNA samples were generated from ear or tail tissue
biopsies. All injection procedures were performed on presymptomatic
P60 mice. Mice were first anesthetized using a mixture of xylazine and
ketamine. Next, 100 l of Neurobasal-containing X10 concentrated len-
tiviruses (6 109 titer units) was injected into the gastrocnemius (GC)
muscles using a 1 ml syringe and a 25G needle. A pLL-miR126-5p-GFP
construct was injected into the right hind foot, whereas a pLL-miR142-
GFP construct was injected into the left hind foot. All animal experimen-
tations were approved by the Tel Aviv University Animal Ethics
Committee.
MFC preparation. Polydimethylsilxane MFCs were designed and cast
as described previously (Ionescu et al., 2016). After the wells were
punched, a small “cave” was created in the explant well near the grooves
using a 25G needle, keeping the explant in place. Microfluidic devices
were cleaned of surface particles using adhesive tape and were sterilized
in 70% ethanol for 15 min. Devices were completely dried under sterile
conditions using UV radiation and then attached to a sterile 60 mm
plastic dish (Nunc) with gentle pressure, and the margins were sealed
with polydimethylsilxane before incubation at 70°C for 30 min to pre-
vent the detachment of the chamber. Muscle channels were coated with
Matrigel diluted 1:10 with DMEM containing 2.5% penicillin-
streptomycin-nystatin (PSN) for 30min at 37°C, before filling themuscle
wells with 150 l of Bioamf-2 medium. The explant well and channel
were filled with 150 l of 1.5 ng/ml poly-DL-ornithine (P-8638, Sigma-
Aldrich) in PBS overnight and then replaced with 150 l laminin (L-
2020, Sigma-Aldrich), 1:333 in deionized distilled water overnight. One
day before plating the SC explant, laminin was replaced with explant
medium containing Neurobasal (Invitrogen) supplemented with 2%
B27 (Invitrogen), 1% penicillin-streptomycin (Biological Industries),
1% Glutamax (Invitrogen), and 25 ng/ml BDNF (Alomone Labs), until
the day on which coculturing began.
Fluorescence microscopy and image analysis. All confocal images were
captured using a Nikon Ti microscope equipped with a Yokogawa CSU
X-1 spinning disc and an Andor iXon897 EMCCD camera controlled by
Andor IQ2 software. Epifluorescence was imaged using the same micro-
scope in bright-fieldmode, and imageswere capturedwith anAndorNeo
sCMOS camera, or at a FLoid benchtop imaging station (Invitrogen).
TIRF images were captured using a TILL photonics iMIC microscope
(FEIMunich) with an Andor iXon897 EMCCD camera. All live-imaging
assays were performed in a humidified 5% CO2 incubation chamber.
Western blotting. Muscle and sciatic nerve (SN) tissues of both sexes
were excised and homogenized in lysis buffer containing PBS, 1% Triton
X-100 (Sigma-Aldrich), and 1protease inhibitors (RocheDiagnostics),
followed by centrifugation and collection of the supernatant. Protein
concentration was determined using the Bio-Rad Protein Assay. Protein
samples were denatured by boiling in SDS sample buffer, which were
then electrophoresed in 10% polyacrylamide gels (SDS-PAGE). Proteins
were transferred to a nitrocellulose membrane and then immunoblotted
with appropriate primary antibodies: Sema3A (Abcam, ab23393;
1:1000); NRP1 (Abcam, ab81321; 1:1000); Sema3B (Abcam, ab48197;
1:2000); NRP2 (Cell Signaling D39A5, 1: 1000); GFP (Abcam ab13970;
1:5000); tubulin (1:10,000) and ERK (1:10,000), diluted in 5% (w/v)
skim milk (BD Difco) in TBS-T, followed by species-specific HRP-
conjugated secondary antibodies (Jackson ImmunoResearch Laborato-
ries; 1:10,000) and visualized using a myECL imager (Thermo Fisher
Scientific), according to the manufacturer’s instructions. Quantification
was performed using ImageJ software.
Isolation and culture of human mesenchymal stem cells (hMSCs).
hMSCs from healthy donors and ALS patients used in this study were
obtained from bone marrow samples and were isolated, and then phe-
notypically characterized and cultured as described previously (Nach-
many et al., 2012). All volunteers in this work signed a consent form
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before sample donation, according to the guidelines of the Hospital’s
Ethics Committee supervised by the Israeli HealthMinistry Ethics Com-
mittee conforming with the Code of Ethics of the World Medical Asso-
ciation (Declaration of Helsinki), printed in the British Medical Journal
(Rickham, 1964).
MN cell culture. Primary SC neurons were cultured using E12.5mouse
embryos of either sex as previously described (Zahavi et al., 2015).
Briefly, SCs were excised, trypsinized, and triturated. Supernatant was
collected and centrifuged through a 4% BSA cushion. The pellet was
resuspended and centrifuged through an OptiPrep gradient (10.4%
OptiPrep, Sigma-Aldrich; 10 mM Tricine, 4% glucose) for 20 min at
760 gwith the brake turned off. Cells were collected from the interface,
washed once in complete medium, and then plated in coated growth
chambers. Cells were maintained in Complete Neurobasal Medium (In-
vitrogen) containing B27 (Invitrogen), 10% (v/v) horse serum (Biologi-
cal Industries), 25 nM -mercaptoethanol, 1% penicillin-streptomycin
(PS; Biological Industries), and 1% GlutaMAX (Invitrogen) supple-
mented with 1 ng/ml GDNF, 0.5 ng/ml CNTF, and 1 ng/ml BDNF (Alo-
mone Labs). Before plating, the growth plates were coated with 1.5 g/ml
poly-DL-ornithine (Sigma-Aldrich) overnight at 37°C and 3 g/ml laminin
(Sigma-Aldrich) for 2 h at 37°C. For immunofluorescence staining,
30,000 cells were plated on cover slides in 24-well plates. Cells were grown
at 37°C in 5% CO2.
SC explants. SCs were dissected from E11.5 mouse embryos of both
sexes, either using HB9::GFP or SOD1G93A stripped of meninges and
DRGs. The ventral horn was separated from the dorsal horn by longitu-
dinal cuts along the SC, and transverse sections up to 1 mm were placed
in the explant well. Before plating, the growth chambers were coatedwith
1.5 g/ml poly-DL-ornithine overnight at 37°C and 3 g/ml laminin over-
night at 37°C. Explants weremaintained in Spinal Cord ExplantMedium
containing Neurobasal, 2% B27, 1% PS, and 1% GlutaMAX, supple-
mented with 25 ng/ml BDNF. Explants were grown at 37°C in 5% CO2.
Primary myocyte culture. Skeletal muscle cultures were derived from
the GCmuscle of adult P60 female mice of either SOD1G93A background
or their littermates (LMs) using techniques previously described (Io-
nescu et al., 2016). Briefly, GC muscles were excised and incubated in 2
mg/ml collagenase I (Sigma-Aldrich) in DMEM containing 2.5% PSN
(Biological Industries) for 3 h. Muscles were then dissociated and incu-
bated for 3 d in Matrigel-coated (BD Biosciences) 6-well plates with
Bioamf-2 medium (Biological Industries) with 1% PSN at a density of
120 myofibers per well. For purification of the myoblasts, adherent
cells were trypsinized and preplated in an uncoated dish for 1 h at 37°C.
Nonadherent cells were then transferred into aMatrigel-coated dishwith
Bioamf-2medium. Preplatingwas repeated for 2 d, keeping the culture at
50% confluence, before plating cells in MFC. Cultures were main-
tained at 37°C and in 5% CO2. After the final preplating, 100,000 myo-
cytes were cultured in the precoated distal compartment of the MFC.
Myocyte conditionedmedia (CM) were produced as follows: At the final
preplating stage, myoblasts were cultured in a Matrigel-coated 100 mm
dish at 80% confluence and were incubated for 2 d with Bioamf-2 me-
dium, followed by 2 d with rich DMEM (Biological Industries) medium
containing 10% FCS (Biological Industries), 10% horse serum (Biologi-
cal Industries), 1% GlutaMAX, and 1% PSN. Then, once muscles
reached a fully differentiated state, the culture dish was rinsed 3 times
with preheated PBS and poorDMEMcontaining 1%GlutaMAX, and 1%
PSN was applied on the cultures. CMwas collected after 2 d, centrifuged
for 5 min at 400 g at 25°C, and streamed through a 0.22mPES filter.
CMpreparationandapplication.Musclemyocytes ofWTorSOD1G93Amice
were cultured as described previously (Ionescu et al., 2016). Seven days
after myocytes were fully differentiated, the muscles kept growing for 3 d
in complete Neurobasal containing BDNF and GDNF. The CM was re-
freshed with BDNF, GDNF, and glucose after its collection, as described
previously (Nagai et al., 2007). CMunder both conditionswas applied on
the axon compartment of the MFC for 48 h.
Lentiviral vectors.Genes of interest were cloned into a third-generation
lentiviral pLL3.7 backbone. HEK293T cells were transfected by using
calcium phosphate method and a mixture consisting of the vector of
interest, vesicular stomatitis virus glycoprotein, and group antigens-
polymerase (reverse transcriptase) was used. The medium was replaced
after 5–8 h, and the supernatant was collected 48 h later. Next, 50 mM
HEPESwas added before freezing tomaintain a neutral pH for long-term
storage. When necessary, lentiviruses were concentrated using a PEG
Virus Precipitation Kit (Abcam).
NMJ staining.GCwas excised fromP60mice and cleared of connective
tissue, washed in PBS, fixed in 4% PFA, washed once more, and then
incubated with 1 g/ml Rhodamine Red-Conjugated Bungarotoxin
(Sigma-Aldrich). Tissues were washed and then treated withmethanol at
20°C for 5 min, washed, and then blocked in blocking solution for 1 h.
Tissues were then rocked with appropriate primary antibodies diluted in
blocking solution at room temperature overnight. Antibodies were used
at the following concentrations: anti-Neurofilament Heavy Chain 1:500
(NFH, Abcam, ab72996; 1:1000), synaptophysin (Millipore, MAB5258;
1:300), synaptotagmin (Alomone Labs, ant-003; 1:300), anti-NRP1 (1:
100), anti-Sema3A (1:100), anti-NRP2 (1:100), and anti-Sema3B (1:
100). After having beenwashed, secondary antibodies (DyLight 405 anti-
chicken 1:500; AlexaFluor-488 anti-chicken 1:500; AlexaFluor-647 anti-
rabbit 1:500) were added for 4 h at room temperature.Muscle fibers were
spread into monolayers under a stereomicroscope and affixed to slides
using VectaShield (Vector Laboratories). Cover slides were sealed with
clear nail polish.
Quantification of myocyte contraction. The 1000-frame-long movies of
myocytes in the distal compartment of the MFC were acquired 7 d after
coculturing. Imaging was performed under bright-field conditions at a
rate of33 fps while using a 20 objective. A myocyte contraction plot
was then profiled using an image-based method previously described
(Zahavi et al., 2015; Ionescu et al., 2016). Briefly, onlymyocytes that came
in contact with axons were plotted. Time-lapse images were taken for
analysis using ImageJ. To create a time trace of contractions, high con-
trast (bright or dark) ROIs were selected on eachmyotube.Movement of
the selected spot due to myotube contraction was assessed by the change
in the ROI intensity over time. The number of strong contractions, as
measured from the time trace, was manually validated by reexamining the
time-lapse image series. The number of strong and weak contractions in
innervatedmyotubeswas comparedbefore andafter1MTTXwasadded to
the neuronal compartment. A myotube with a post- to pre-TTX difference
of50% was measured as an increase or decrease in contraction, and the
fraction of increased, decreased, and unchangedmyotubes was calculated.
Immunostaining of cell cultures. Cultures were fixed in 4% PFA and
permeabilized with 0.1% Triton X-100, 5% DS (Donkey Serum), 1
mg/ml BSA in PBS. Samples were blocked for 1 h with blocking medium
containing 5%DS, 1mg/ml BSA in PBS. Primary antibodies againstNFH
(1:500), NRP1 (1:100), Sema3A (1:100), NRP2 (1:100), Sema3B (1:100),
and acetylated tubulin (1:1000), ryanodine receptor 1 (Millipore,
AB9078; 1:500),-actinin (Sigma-Aldrich, A5044; 1:400), Tau5 (Abcam,
ab80579; 1:500) MAP2 (Millipore, ab5622; 1:500) were diluted in block-
ing solution and incubated overnight at 4°C. Samples were incubated
with species-specific fluorescent secondary antibodies for 2 h at room
temperature. DAPI was used for visualizing nuclei inmyotubes. InMFC,
after the staining protocol was completed, the MFC was peeled from the
dish by gently pulling it from the proximal to the distal side. ProLong
mounting medium was added, and samples were covered with a #1.5,
18 18 mm coverslide.
RNA extraction and cDNA synthesis.Muscle tissues were immediately
frozen with liquid nitrogen. Tissue was ground to powder using a pestle
andmortar. Then 700l of TriReagent (Sigma-Aldrich)was added to the
muscle powder, and the samples were further passed through a 21G
needle 3 times for better homogenization. RNA from the TriReagent-
rinsed samples was further isolated following the TriReagent protocol.
RNA quality was measured using NanoDrop3000 and a bio-analyzer.
RNA purification ofMNmass culture, along with transfected HeLa cells,
was performedusingTriReagent protocol aswell.mRNAswere pooled in
equal amounts and reverse-transcribed into double-stranded cDNA by
using the SuperScript2 kit (QIAGEN).
NanoString Chip. A total of 100 ng RNA samples were outsourced to
NanoString Technologies’ facilities for anmiR-Chip array assay of800
knownmiRs (NanoString Technologies). miR was quantified automat-
ically by NanoString Technologies’ instrumentation for miRs, which
was hybridized with the template. Output data were analyzed by the
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nCounter analysis system. All miRs were normalized to the 100 most
abundant miRs in the samples.
Primer design. Based on the consensus sequences of the desired tran-
scripts, 2 sets of primers were designed for each gene (Table 1).
qPCR for mRNA detection. qPCR was performed on the StepOne sys-
tem (Invitrogen) in a 10l reaction containing 4l of RNA (20 ng), 5l
Syber green master mix (Thermo Fisher Scientific), and 1 l of reverse
and forward primers.
miR vectors and transfection. Mammalian expression vector pMSCV-
Blast-miR constructs were generously provided by Eran Hornstein
(Weizmann Institute of Science). Mammalian expression vector of
C9orft72 Di-peptide PR50 and GR50 constructs was generously provided
by David Trotti (Jefferson University) (Wen et al., 2014). Next, 50,000
HeLa/U87 human glioblastoma/muscles cells were plated in richDMEM
(1% PS, 1% GlutaMAX, 20% FBS). After 24 h, the culture medium was
replaced with serum-free medium (Opti-MEM), and cells were trans-
fected using FuGene NE 6 (Promega) protocol. Cells were collected after
48 h and used either for a functional assay or for RNA/protein extracts.
Myocyte cultures were transfected using the same approach.
Semaphorin preparation. HEK293T cells were stably transfected to
overexpress either Sema3Aor an empty control. CM from80%confluent
cultures were collected after 3 d. We validated the purity level of the
collectedmedia usingCoomassie staining and identified the stained band
with a specific antibody against the desired protein using Western blot
analysis.
NRP1 antibody application. A total of 5 g/ml NRP1 antibody (R&D
System, AF566 dot ETH0915031) for the extracellular domainwas added
to the distal compartment of the MFC while maintaining a proximal-to-
distal volume gradient.
Histology tissue collection and fixation. GCmuscles of 20 samples were
harvested and fixed in 4% PFA. The samples were then outsourced for a
histological assessment at Patho-Logica. All tissues were trimmed into
block cassettes and sent to CDX Diagnostics for slide preparation.
Slide preparation and histological evaluation. Tissues were trimmed,
embedded in paraffin sections at no more than 5 m thickness, and
stained with H&E. The mean minimal muscle fiber diameter thickness
wasmeasured inmicrons by performing amanual count using a 10 lens
and analyzed by expert pathologist.
xCELLigence impedance measurement. For each experiment, 30,000
U87 cells were plated with rich DMEM in E-Plate L8 wells and incubated
together with the xCELLigence system (ACEA Biosciences) at 37°C, 5%
CO2 overnight. Impedance data were collected at 5 min intervals. After
24 h, poor DMEM (1% PS, 1% GlutaMAX) with Sema3A or its control
medium was replaced and recording proceeded. The data were analyzed
using RTCA data analysis software 1.0 and normalized to the control
sample.
CatWalk XT gait analysis. The CatWalk is a video-based analysis sys-
tem used to assess gait in voluntarily walking mice (Noldus Information
Technology). The principle of this method is based on an optical tech-
nique. The light of a fluorescence tube is completely internally reflected
on a glass walkway floor. When the animal crosses the walkway, the light
leaves the glass and illuminates only the area of contact. In this way, the
different paw contacts are visualized. Based on position, pressure, and
the surface area of each foot paw, multiple parameters are calculated.
Only compliant and continuing trials for each animal were analyzed,
averaged, and the mean was calculated.
Experimental design and statistical analysis.Data aremean SEM. The
statistical analysis was assessed by Student’s t test. In all cases, differences
were considered to be statistically significant if p 0.05.
Results
Sema3A and NRP1 levels are elevated in muscles and theMNs
of ALS models
ALS disease is considered to be a distal axonopathy involving
axon degeneration and NMJ disruption as key processes in its
pathology (Fischer et al., 2004). We therefore hypothesized that
destabilizing factors secreted from adult presymptomatic ALS
mutant muscles might be involved in triggering axon degenera-
tion of MNs. Because Sema3A is known to act in such a manner,
at least in development, and it was already reported to be elevated
in ALS, we decided to focus on this factor (DeWinter et al., 2006;
Ko¨rner et al., 2016). Following this hypothesis, we first examined
the expression of Sema3A in SOD1G93A GC muscles in compari-
son with that of their LMs; (Fig. 1A,B; Fig. 1-1, available at
https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f1-1). West-
ern blot analysis of muscle protein extracts revealed significant
elevations in Sema3A protein levels in muscles of presymptom-
atic SOD1G93A mice as early as P30 and P60, whereas testing
Sema3A levels in younger animals (P7) showed no apparent dif-
ferences compared with their LM controls (mean fold change
over LM: P30 SOD1G93A, 3.08  0.86; P30 LM, 1  0.36; P60
SOD1G93A, 2.2 0.45; P60 LM, 1 0.32; P7 SOD1G93A, 1.2 0.7;
P7 LM, 1  0.42). To validate this difference, we also tested the
transcript levels of Sema3A (Fig. 1C). qPCR analysis of total RNA
extracts from muscles at presymptomatic SOD1G93A stage and
LM mice identified an 1.7-fold increase in Sema3A mRNA of
SOD1G93A muscles (mean fold change over LM: SOD1G93A,
1.72  0.32; LM, 1  0.06). Because GC muscle tissues contain
heterogeneous cell types and to verify that the levels of Sema3A
are indeed higher specifically in SOD1G93A muscles fibers, we
immunostained primary myocyte cultures from P60 SOD1G93A
and LM mice for Sema3A (Fig. 1D,E). Quantifying the mean
intensity values showed a significant 50% increase in the
SOD1G93A myocytes (a mean fold change in intensity over LM:
SOD1G93A, 1.5 0.06; LM, 1 0.04).We also collected CM from
myocyte cultures to determine whether the increase in Sema3A
protein also results in an increase in its secretion (Fig. 1F). West-
ern blot analysis indicated that Sema3A levels were also elevated
in P60 SOD1G93A myocyte-CM (a mean fold change over LM:
SOD1G93A, 2.3 0.55; LM, 1 0.08). Because NMJ disruption is
a primary event in ALS, we sought to examine the levels of
Sema3A in NMJ in vivo (Fig. 1G,H). Immunostaining for
Sema3A in GC muscles showed a sixfold increase in the number
of muscle fibers expressing Sema3A in their NMJs. Whereas only
5% of NMJs stained positively for Sema3A in LM muscles, we
identified its expression in30%ofNMJs in P60 SOD1G93Amice
(the mean percentage of NMJs expressing Sema3A: SOD1G93A,
30.83 4.73%; LM, 4.56 2.4%). Interestingly, a previous study
described Sema3A elevation in SODG93A mice specifically in fast
fatigue NMJs expressing myosin-IIb marker (De Winter et al.,
2006). Because fast fatigueNMJs are the first to becomedisrupted
and be eliminated in ALS pathology, we examined Sema3A levels
both at P90 and P120 and hypothesized that Sema3A levels will
eventually drop in later stages of the disease. We found that
whereas the percentage of NMJs expressing Sema3A in SODG93A
in P90 animals is similar to P60, the end-stage animals (P120)
were shown to display a reduction in Sema3A-positiveNMJs, and
Table 1. Primer design
Gene Forward primer Reverse primer
hHPRT GAACCAGGTTATGACCTTGATTTAT GCAAGACGTTCAGTCCTGT
hSema3A GCTCCAGTTATCATACCTTCCTTTTG ACTGGCCACACAATCTTTTGAA
hNRP1 ACCTGTTCTCTTTCAGGGAA CAAGTTGCAGGCTTGATTCG
hB2M CCGTGTGAACCATGTGACTT GGCATCTTCAAACCTCCATGA
hNRP2 GAGGCCAACCAGACCCA CGTAAACAATCCACTCGCAGTT
hSema3B TCTCCTTCCAAGTCCA CTCGGCACCCACAAACA
mSema3A CACTGGGATTGCCTGTCTT GGCCAAGCCATTAAAAGTGA
mGFP GCTACCCCGACCACATGAAGCA GTCTTGTAGGTGCCGTCGTCCTTG
m-miR126 ID000451 (Thermo Fisher Scientific) ID000451 (Thermo Fisher Scientific)
h, Human gene; m, murine gene.
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Figure1. Presymptomatic elevation in the levels of Sema3AandNRP1 inALSmodels.A,B,Westernblot analysis of P30andP60GCmuscle extracts revealed that the levels of Sema3Aare elevated
in presymptomatic SOD1G93Amuscles compared with their corresponding LM control wherein at earlier stages we found no significant difference (Figure 1-1, available at https://doi.org/10.1523/
JNEUROSCI.3037-17.2018.f1-1). Tubulinwas used as a loading control. P30 (Student’s t test, n 3, *p 0.042). P60 (Student’s t test, n 4, *p 0.038). C, qPCR analysis of presymptomatic P60
and P30 GCmuscle extracts also shows an elevation in themRNA levels of Sema3A in SOD1G93A (Student’s t test, SOD1G93A, n 5, LM, n 4, *p 0.049).D, Immunostaining of primarymyocytes
after 7 d in culture shows elevated levels of Sema3A in primary myocytes of SOD1G93A. White represents Sema3A. Blue represents nuclear DAPI staining. Scale bars, (Figure legend continues.)
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no apparent difference existed between WT and SOD1G93A mice
(Fig. 1-2A,B, available at https://doi.org/10.1523/JNEUROSCI.
3037-17.2018.f1-2). Together, these results indicate that a signifi-
cant part of the MN population is exposed to high levels of
Sema3A in presymptomatic stages and that this specific popula-
tion is disrupted and eliminated during disease progression. We
then proceeded to investigate the expression of the Sema3A-
receptor binding unit, NRP1, in ALS (Fig. 1I).Western blot anal-
ysis of GCmuscle extracts revealed a significant8-fold increase
in NRP1 (the mean fold change over LM: SOD1G93A, 8.6  2.2;
LM, 1  0.3). Because MNs are a primary target in ALS, we
wanted to determine whether NRP1 is also overexpressed in the
MNs of SOD1G93A mice. First, we performed Western blot anal-
ysis of SNs and observed an2-fold elevation in NRP1 levels of
P60 SOD1G93A mice (Fig. 1J; the mean fold change over LM:
SOD1G93A, 1.96 1.22; LM, 1 0.21). Next, we obtained protein
extracts of primary MN cultures for Western blot analysis and
confirmed an 2.5-fold elevation in NRP1 levels in the MNs of
SOD1G93A culture (Fig. 1K; the mean fold change over LM:
SOD1G93A, 2.3  0.16; LM, 1  0.06). Immunostaining of pri-
mary MN cultures for NRP1 resulted in analogous findings (Fig.
1L–N). Intriguingly, the NRP1 signal in SOD1G93A is generally
higher than in LM and is increased evenmore in axons compared
with cell bodies (themean fold change over LM: SOD1G93A soma,
1.86 0.13; LM soma, 1 0.05; SOD1G93A axon, 3.83 0.95; LM
axon, 1 0.11). Finally, immunostaining for NRP1 in GC mus-
cles confirmed a similar shift of 30% in the number of NMJs
expressing NRP1, as we had observed for Sema3A in SOD1G93A
mice, both at P60 and P90. However, also this time, the differ-
ences were abolished in the end stages of the disease (P120) (Fig.
1O,P; Fig. 1-2C,D, available at https://doi.org/10.1523/JNEURO-
SCI.3037-17.2018.f1-2; the mean percentage of NMJs expressing
NRP1: P60: SOD1G93A, 27.5  2.04%; LM, 21.27  1.22%). To
determine whether the elevatedNRP1 levels result from feedback
due to an increase in its ligand, we treated primary MN cultures
from LM embryos with soluble Sema3A for 3 d and performed
Western blot analysis on cell culture lysates. Importantly, we did
not observe any difference in NRP1 expression after applying
Sema3A, suggesting that NRP1 levels are regulated by an intrinsic
mechanism in MNs (Fig. 1-3, available at https://doi.org/
10.1523/JNEUROSCI.3037-17.2018.f1-3). Finally, to validate our
finding with other ALS models and to emphasize the impact of
Sema3A in ALS, we performed Western blot analysis for Sema3A
and NRP1 expression in humanmesenchymal stem cells from spo-
radic ALS patients and healthy controls, as well as in myocyte-
expressingC9orf72-PR50 and their CM for Sema3A. In addition, we
compared the results with those of a mock control. Remarkably, in
allof theseALSmodels,we identifiedhighexpressionofSema3Aand
NRP1 (Fig. 1-4, available at https://doi.org/10.1523/JNEUROSCI.
3037-17.2018.f1-4).
Together, our combined in vivo and in vitro data suggest that
the levels of both Sema3A and its cobinding receptor, NRP1, are
presymptomatically increased in several ALS models as well as in
sALS patients. These findings suggest that the Sema3A pathway is
a common denominator in various ALS mutations; thus, it may
contribute to MN degeneration in ALS.
Application of Sema3A on wild-typeMN axons results in
axon degeneration
Because our findings suggest that Sema3A is produced and se-
creted in excess from muscles of ALS models, and because mus-
cles interact specifically with MN axons, we sought to test the
activity of Sema3A exclusively in this distal subcellular compart-
ment. To this end, we used an MFC that allows precise control,
monitoring, and manipulation of subcellular microenvironments
(Fig. 2-1, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f2-1) (Zahavi et al., 2015).We cultured healthy ventral SC
explants from transgenic mouse embryos expressing GFP under
the MN-specific promoter HB9 (HB9::GFP) in one compart-
ment of the MFC and enabled axons to extend into the opposing
compartment, thus segregating axons and cell bodies into two
isolated compartments. To verify that our MFCs can efficiently
segregate MN axons from their somata, we stained the neuronal
culture in the MFC system for the dendritic and axonal markers
MAP2 andTau, respectively (Fig. 2-1, available at https://doi.org/
10.1523/JNEUROSCI.3037-17.2018.f2-1). We confirmed that all
neurites that traversed the distal compartment are positive for
Tau staining and negative for MAP2. Next, we purified Sema3A
or control media as described previously (Ben-Zvi et al., 2006),
and applied them to the distal compartment, while imaging the
axons for 16 h (Fig. 2A). Our recordings reveal extensive axon
degeneration in the Sema3A-treated MFCs 6–8 h after its appli-
cation (Fig. 2B; Movies 1, 2; the mean percentage of degenerated
axons: Sema3A, 83.01  3.54%; control, 23.94  7.6%). Coap-
plication of NRP1-blocking antibody and Sema3A onMN axons
inhibits the Sema3A-dependent axon degeneration (Fig. 2B; the
mean percentage of degenerated axons: Sema3A and NRP1 anti-
body, 25.00 12%). These data indicate that Sema3A can trigger
axon degeneration in MNs when applied exclusively on distal
axons, and further support our hypothesis that an increase in
muscle-derived Sema3A might contribute to axon degeneration
in ALS.
4
(Figure legend continued.) 5m.E, Imageanalysis reveals an increase in Sema3A intensity in
SOD1G93A primary myocytes (Student’s t test, n 3,80 cells, ***p 0.00001). F, Western
blot analysis of primary myocyte-CM revealed a higher level of Sema3A in the CM of SOD1G93A.
Cultures were lysed after CM collection, and equal loading volumes of lysates were immuno-
blotted for ERK to validate CM,whichwas produced from a similarmass ofmyocytes (Student’s
t test, n 3, *p 0.018).G,H, Immunostaining of fixedwhole P60 GCmuscles shows distinct
Sema3A expression in the NMJs of SOD1G93A mice. White represents Sema3A. Red represents
TMR-BTX labeling of acetylcholine receptors on postsynapse. Blue represents presynaptic NFH
in neurons. The percentage of muscle fibers expressing Sema3A in their NMJs in P60 SOD1G93A
mice is higher (100 NMJ per 1 biological repeat; Student’s t test, SOD1G93A, n 4; WT, n
3; *p 0.011). Scale bars, 10m.We also examined Sema3A expression in later stages of the
disease (Figure 1-2, available at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f1-2). I,
Western blot analysis of GCmuscle extracts from P60mice revealed elevated NRP1 levels in the
muscles of SOD1G93A. Tubulin was used as a loading control (Student’s t test, n 3, *p
0.048). J, Western blot analysis of SN extract from P60mice shows an elevation in the levels of
NRP1 in the SNs of SOD1G93Amice (n 3). K, Western blot analysis of primaryMN lysates after
3 d in culture reveals an elevation in the NRP1 levels in SOD1G93AMNs, which are not regulated
by Sema3A binding (Figure 1-3, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f1-3). ERK was used as a loading control (Student’s t test, n 3, *p 0.031). L–N,
Immunostaining of primary MNs after 3 d in culture shows an elevation in the levels of NRP1 in
both axons (inset,4.1-fold) and somata (1.9-fold) of SOD1G93A MNs. White represents
NRP1.Blue representsNFH. Somata (Student’s t test,n3,40cells, ***p0.00021); axons
(Student’s t test, n 3,40 cells, *p 0.012). Scale bars, 10m. O, P, Immunostaining of
fixed whole P60 GC muscles shows distinct NRP1 expression in the NMJs of SOD1G93A mice.
White represents NRP1. Red represents BTX. Blue represents NFH. The percentage of muscle
fibers expressing NRP1 in their NMJs in P60 SOD1G93Amice is higher (Student’s t test, SOD1G93A,
n 4; WT, n 3; *p 0.042). Scale bars, 5m. We further examined NRP1 expression in
later stages of the disease (Figure 1-2, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f1-2). Elevations in Sema3A and its coreceptorwere found also in human sALS samples
(Figure 1-4, available at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f1-4). A–C, E, F,
I–K,M, N, Data represent the mean fold difference over the LM control SEM.
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Figure 2. Sema3A as well as primarymyocytes expressing diverse ALS-causingmutations impair the growth of wild-type HB9::GFPmotor axons and enhance their retraction and degeneration.
A, Experimental procedure illustration and representative time-lapse images of HB9::GFPmotor axons (Figure 2-1, available at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f2-1) in the distal
compartment of an MFC with no muscles after applying Sema3A to the distal compartment. After 6 h, axons in the distal compartment of chambers that were treated with Sema3A undergo
degeneration,whereas axons in the control chamber or axons cotreatedwith NRP1 antibody and Sema3A continue growing. Scale bar, 20m.B, Quantification of the rate of degraded axons in the
distal compartment revealed a higher percentage of degradation in chambers that were exposed to Sema3A compared with either control or coapplication of Sema3A and NRP1 antibody (60
axons for Sema3A treatment,70 axons for Control; Student’s t test; n 4; mean SEM, ***p 0.00022). C, Schematic view of the experimental procedure in D–F. HB9::GFP SC explants and
primary myocytes of SOD1G93A, TDP43A315T, C9orf72-PR50, C9orf72-GR50, or LM, GFP, and SOD1
wt as controls were cocultured in an MFC (Figure 2-2, available at https://doi.org/10.1523/
JNEUROSCI.3037-17.2018.f2-2), and thegrowthofHB9::GFPaxonswas assessedby time-lapse imagingof themicrogroove compartment.D, Representative time-lapse images of theHB9::GFPaxon
growthwhen coculturedwith (left to right) LM, SOD1G93A, and SOD1G93A	NRP1 antibody. The presence of SOD1G93Amyocytes in the distal compartment triggers the retraction and degeneration
of HB9::GFP motor axons growing in the groove compartment and prevents their traversing. When NRP1 antibody is applied to the distal compartment, together with SOD1G93A-expressing
myocytes, axons are less prone to degenerate. Scale bar, 5m. E, Quantification of the rate of axons traversing the distal compartment inB shows themean percentage of axons that traversed the
distal compartment out of the total axons in each field (n 3; NRP1 antibody experiment, n 4; Student’s t test, *p 0.025, *p 0.0433). F, Quantification of (Figure legend continues.)
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Muscles expressing diverse ALSmutations initiate
axon degeneration
To study the molecular mechanisms enabling the communica-
tion betweenMNs and their environment, which are essential for
cell survival and synapsemaintenance, we extended the use of the
MFC system to coculture primary MNs and primary myocytes
(Ionescu et al., 2016). Briefly, ventral SC explants from healthy
12-day-old (E12) HB9::GFP embryos were cultured in the prox-
imal compartment, in the presence or absence of primary myo-
cytes extracted from adult mice in the distal compartment
(Fig. 2-1, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f2-1). As we showed previously (Zahavi et al., 2015),
culturing HB9::GFP explants in the presence of wild-type mus-
cles facilitates the rapid and directed growth of axons into the
distal compartment (Fig. 2-1, available at https://doi.org/
10.1523/JNEUROSCI.3037-17.2018.f2-1), suggesting that mus-
cles secrete factors that support andpromote the growth ofmotor
axons. However, because ALS-mutated muscles were found to
have intrinsic abnormalities throughout disease progression
(Loeffler et al., 2016), we hypothesized that the nature of these
factors will be altered. To study the effect of ALS muscles onMN
axons in a simplified system, we plated primary myocytes from
presymptomatic P60 SOD1G93A and LMmice as well asWTmyo-
cytes transfected to express SOD1wt in the distal compartment.
Myocyte cultures were allowed to fuse and differentiate. Impor-
tantly, in all the described cases, myocyte morphology, fusion,
and differentiation parameters were similar, and the culture
showed no apparent difference (Fig. 2-2, available at https://
doi.org/10.1523/JNEUROSCI.3037-17.2018.f2-2). After 7 d,
HB9::GFP SC explants were cultured in the proximal compart-
ment. Cocultures were incubated until the HB9::GFP axons be-
gan extending toward the microgroove compartment. Once the
axons reached the microgroove compartment, the extension of
HB9::GFP axons along the microgrooves was recorded for 16 h
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(Figure legend continued.) the rate of axons traversing the distal compartment shows the
mean percentage of axons that traversed the distal compartment out of the total number of
axons in each field in coculturewith TDP43 A315T, C9orf72-PR50 , C9orf72-GR50myocytes, or GFP
as a control. The traversing rate of HB9::GFPmotor axons into the distal compartment in each of
the cocultureswithmuscle-expressing ALSmutations is significantly reduced (n 3; Student’s
t test, GR50 , *p 0.0137; PR50 , *p 0.0374; TDP, *p 0.0304).G, Representative images of
fixed and immunostained SOD1G93A motor axons in the distal compartment of an MFC after
applying LM or SOD1G93Amyocyte CM to the distal compartment. After 48 h, axons in the distal
compartment of chambers that were treated with SOD1G93A CM underwent degeneration,
whereas axons that were treated with LM CM remained intact. WT MN axons remained
intact after application of either CM (Figure 2-3, available at https://doi.org/10.1523/
JNEUROSCI.3037-17.2018.f2-3). When NRP1 antibody is applied to the distal compartment,
togetherwith SOD1G93A CM, axons are less prone to degenerate, suggesting the involvement of
multiple factors (Figure2-4, available at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f2-
4). Green represents acetylated tubulin. Scale bar, 20 m. H, Quantification of the rate of
degenerated SOD1G93A axons in the distal compartment treatedwith control CM, SOD1G93A CM,
or SOD1G93ACMthatwas coincubatedwith anti-NRP1antibody (Student’s t test;n3; ***p
5 107, *p 0.018). **p 0.01.
Movie 1. Sema3A control medium on HB9::GFP distal axons. Time-
lapse image series of HB9::GFP axons in the distal compartment of an
MFC with control medium added to the distal compartment. Scale bar,
50m.
Movie 2. Sema3A in the distal compartment drives the degenera-
tion of HB9::GFP distal axons. Time-lapse image series of HB9::GFP ax-
ons in the distal compartment of an MFC with Sema3A added to the
distal compartment. Scale bar, 50m.
Movie 3. HB9::GFP axonal growth toward SOD1G93A myocytes.
Time-lapse image series ofHB9::GFPaxons in themicrogroove compart-
ment of an MFC with SOD1G93A myocytes in the distal compartment
(top). Scale bar, 50m.
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(Fig. 2C). Surprisingly, HB9::GFP axons that were cocultured
with the SOD1G93Amyocytes were less likely to traverse the distal
side (Fig. 2D,E). During this period, axons extending toward the
SOD1G93A myocytes were markedly incapable of traversing the
distal compartment and underwent retraction, degeneration, or
remained static in place, compared with the LM and SOD1wt
controls (Fig. 2D; Movies 3, 4). Noteworthy, the addition of
NRP1-blocking antibodies to the distal compartment, targeting
Sema3A binding to the extracellular site of NRP1, improved the
traversing rate of axons (Fig. 2E; the mean axon traversal rate per
field: LM, 33.88  10.40%; SOD1wt, 52.66  12.7% SOD1G93A,
11.1  5.5%; SOD1G93A	NRP1-ab, 28.18  5.4%). We further
transfected primary myocyte cultures with several more ALS-
linked mutations or aberrant toxic proteins as follows: C9orf72-
PR50, C9orf72-GR50 (Wen et al., 2014), and TDP43
A315T and
used empty-GFP vector as a control. Transfected myocytes ex-
hibit normalmorphology and fusion in comparison with theWT
muscle culture in our system (Fig. 2-2, available at https://
doi.org/10.1523/JNEUROSCI.3037-17.2018.f2-2). Nevertheless,
all ALS-causingmutations that we examined recapitulated the phe-
notypes we described previously in SOD1G93A (Fig. 2F; GFP,
40.65  16%; GR50, 5.2  3.49%; PR50, 0  0%; TDP43
A315T,
8.75 6.39%). These results suggest that the dysregulated secre-
tion of factors from ALS mutant muscles takes place, which in
turn activates axon retraction and degeneration. Becausemuscles
can either secrete positive or negative signaling molecules, we
could not determine whether our observation within this assay
originates from an increase in the release of destabilizing factors
or the diminished release of positive factors. To this end, we
collectedmuscle-CM fromWT and SOD1G93Amuscle cultures in
complete medium containing positive factors, such as BDNF
and GDNF, as was previously performed in mass culture (Na-
gai et al., 2007), and ultimately applied it only to the distal axons
of both WT and SOD1G93A MNs (Fig. 2G,H). Interestingly, we
observed that axon degeneration occurs only when SOD1G93A
myocyte-CM is applied to SOD1G93A axons (Fig. 2H; LM, 3.72
1.15%; SOD1G93A, 34.7 4%), whereas in all other combinations
the axons remained intact (Fig. 2-3, available at https://doi.org/
10.1523/JNEUROSCI.3037-17.2018.f2-3). To further determine
whether Type 3 Semaphorins, such as Sema3A, contribute toMN
axon degeneration in this assay, we investigated whether NRP1-
blocking antibody application can block this phenotype. Here
again, we observed a rescue effect by this treatment (Fig. 2H;
SOD1G93A 	 NRP1-antibody 18.6  7%), although the protec-
tion was incomplete. These results reinforce our hypothesis, sug-
gesting that ALS-mutated muscles secrete destabilizing factors,
such as Sema3A. Importantly, these results emphasize that
SOD1G93A MNs exhibit a higher sensitivity to degeneration, and
support the MN unique vulnerability as well as the non–cell-
autonomousmechanismofALS. Interestingly, previous attempts
to block Sema3A signaling in SOD1G93A mice using either a sim-
ilar antibody approach or by crossing transgenic mice expressing
a truncated form of Sema3Awith SOD1G93Amice also resulted in
only amild improvement or none at all ofmotor functions (Ven-
kova et al., 2014;Moloney et al., 2017). This suggests that Sema3A
plays a complex role in MNs and that perhaps other related pro-
teins are involved. This also led us to investigate whether a wider
deregulation of secreted factors released by the diseased muscles
exists. Indeed, examining other members of the Semaphorin
family, we found that the percentage of NMJs expressing
Sema3B, as well as NRP2 is elevated in the SOD1G93A ALS model
(Fig. 2-4, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f2-4). Therefore, we concluded that the destabilizing effect
of ALS muscles over MN axons involves more than a single factor;
thus, it cannotbeblockedorrescuedby targetingone factorata time.
Moreover, the multiplicity of effectors suggests that a higher-order
regulator, such as miRNA, might be involved in this process.
miR126-5p is downregulated in ALSmodels andmodulates
Sema3A, Sema3B, NRP1, and NRP2 protein expression levels
To identify the mechanism underlying the elevated levels of var-
ious secreted destabilizing factors in muscles of ALS models, we
scanned for alterations in miRNAs (mIRs) that can regulate the
expression of multiple proteins. miRs have been previously
linked to MN toxicity in ALS (Haramati et al., 2010). We used
Nanostring miRNA-chip technology to screen for alterations in
800miRs of presymptomatic P60 SOD1G93Amice and their LM
controls. The screen yielded 8 significantly altered miRs (Fig. 3A;
Fig. 3-1, available at https://doi.org/10.1523/JNEUROSCI.3037-
17.2018.f3-1). Because we found that Sema3A levels were ele-
vated in muscles, we narrowed our focus to those miRs that were
reduced and that could regulate its expression, specifically
miR126-5p and miR133a (Fig. 3B; the mean fold change over
LM: SOD1G93A, 0.74  0.03; LM, 1  0.03; Fig. 3-1, available at
https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f3-1). A tar-
geted search for these miRs in databases (miRDB, Pictar, miR-
base, and miRTarBase) revealed that both miRs are predicted to
regulate Semaphorin signaling genes as well as other relevant
transcripts of ALS-related genes. Interestingly, we previously de-
scribed deep-sequencing analyses of primary MN cultures ex-
pressing SOD1G93A or TDP43A315T and demonstrated that
miR126-5p is also correspondingly decreased in diseased MN
axons, but not in their soma (Rotem et al., 2017). This informa-
tion led us to further focus our investigation on miR126-5p. We
used qPCR to validate that miR-126–5p levels in SOD1G93A GC
muscles point to a similar trend (Fig. 3C; the mean fold change
over LM: SOD1G93A, 0.47  0.2; LM, 1  0.45). To verify that
miR126-5p can regulate the expression of Semaphorin3 and
Neuropilin signaling members, we transfected HeLa cells, which
are known to endogenously express Sema3A, Sema3B, NRP1,
and NRP2 (Fujita et al., 2001), with miR126-5p or with the irrel-
evantmiR142, which is not predicted to target any of these genes,
Movie 4. HB9::GFP axonal growth toward LMmyocytes. Time-lapse
image series of HB9::GFP axons in the microgroove compartment of an
MFC with LM myocytes in the distal compartment (top). Scale bar,
50m.
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as a negative control. To this end, we isolated RNA from these
cultures and performed qPCR analysis to determine the mRNA
levels of Sema3A, Sema3B, NRP1, and NRP2 (Fig. 3D–G). Our
results indicate that miR126-5p specifically targets Sema3A,
NRP1, Sema3B, andNRP2 (RT-PCR:mean
Ct-NRP1:miR126,
3.79 0.71; miR142, 2.83 0.57;
Ct-Sema3A: miR126, 4.84
0.22; miR142, 3.84  0.34; 
Ct-NRP2: miR126, 7.6  0.30;
miR142, 6.2 0.37; 
Ct-Sema3B: miR126, 8.1 0.10; miR142,
7.05 0.14). To investigate whether miR126-5p overexpression
can also inhibit Sema3A function, we used a recently described
impedance-based approach. U87MG human glioblastoma cells,
which express NRP1 (Fig. 3-2A, available at https://doi.org/
10.1523/JNEUROSCI.3037-17.2018.f3-2) and were used previ-
ously specifically in this assay (Birger et al., 2015), were
transfected to overexpress miR126-5p or miR142 as a control.
One day after transfection, cells were resuspended and plated in
xCELLigencemultiwell electric plates. The next day, Sema3Awas
added to the cultures, and any morphological or adhesive
changes were monitored by the impedance readout. As demon-
strated by TIRF imaging (Fig. 3H), adding Sema3A to responsive
cells, such as U87MG cells, induces their detachment from the
culture dish. This detachment can be measured as a decrease in
impedance (Fig. 3-2B, available at https://doi.org/10.1523/
JNEUROSCI.3037-17.2018.f3-2). Shortly after Sema3Awas added
to the cultures, cells expressingmiR142 exhibited decreased imped-
ance, whereas cells expressing miR126-5p did not respond to
Sema3A in the medium and kept growing with a corresponding
increase in impedance (Fig. 3I). Hence, we showed that the excess
production of destabilizing factors in ALS is likely to be mediated
downstream of a deregulation inmiR126-5p.
Figure 3. miR126-5p is depleted in SOD1G93A muscles and regulates Sema3 and NRP expression. A, NanoString chip screen heat map of significantly altered miRs in P60 muscles of SOD1G93A
compared with LMmice (extended table under Figure 3-1, https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f3-1). Red and green represent a high or low abundance of miRs, respectively. *p
0.05 (Student’s t test; n 3).B,miR126-5pwas themost significantly downregulatedmiRNA in SOD1G93Amuscles (Student’s t test; n 3, **p 0.003). C, qPCR analysis of P60GCmuscle extracts
further validates thedecrease inmiR126-5p in SOD1G93A (n3).D–G, qPCRanalysis of Sema3A,NRP1, Sema3B, andNRP2 transcript levels inHeLa cells overexpressing eithermiR126-5pormiR142
demonstrates a reduction in their expression levels specifically under miR126-5p overexpression (Student’s t test; n 3, *p 0.0438, *p 0.034, *p 0.031, and *p 0.0434, respectively).
H, Representative TIRF images of U87MG cells reveal a detachment of the cell membrane from the culture dish surface after Sema3A is added to the culturemedium. Scale bar, 10m. I, Impedance
recording of live cells over time shows that U87MG cells overexpressing miR126-5p are unresponsive to Sema3A added to the culture medium because their impedance continuously increases,
whereas the impedance of U87MG cells overexpressing miR142 decreases after treatment (Figure 3-2, https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f3-2).
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Overexpression of miR126-5p can block SOD1G93A
muscle toxicity
We overexpressed miR126-5p in SODG93A myocyte cultures and
quantified Sema3A levels in their culture extract as well as in their
CM. Western blot analysis indicated that Sema3A levels in both
the culture extract and CM are depleted, compared with miR142
(Fig. 4A,B; the mean fold change over SOD1miR142: Muscle
extract-SOD1miR126, 0.24  0.1; SOD1miR142, 1  0.4 Muscle-
CM-SOD1miR126, 0.63 0.03; SOD1miR142, 1 0.13). Next, we
investigated whether overexpressing miR126-5p in both
SOD1G93A and PR50 myocytes can rescue the negative effect on
MN growth that we observed before. To this end, primary myo-
Figure 4. Overexpression of miR126-5p in primary SOD1G93Amyocytes blocks motor axon degeneration and preserves NMJ activity in a compartmental coculture. A, B, Western blot analysis of
transfected myocyte extract overexpressing miR126-5p or miR142 and their CM validates miR126-5p as a regulator of Sema3A specifically in muscles. ERK was used as a loading control (Student’s
t test, n 3, *p 0.0499 and *p 0.05, respectively). C, Schematic view of the experimental procedure inD, E. HB9::GFP SC explants and primarymyocytes of SOD1G93Amice were cocultured in
aMFC. Thegrowthof theHB9::GFP axonswas assessedbothby time-lapse imagingof themicrogroove compartment andby imaging axons that traversed thedistal compartment.D, Representative
time-lapse images andquantificationofHB9::GFPaxongrowthwhencoculturedwithSOD1miR126myocytes (top) or SOD1miR142myocytes (bottom). SOD1miR126myocytes in thedistal compartment
enhanced the axonal traversal of the distal compartment compared with the SOD1miR142 myocytes. The data are shown as themean rate of axons that traversed the distal compartment out of the
total number of axons in each field SEM (Student’s t test,n 3, *p 0.04216). E, Representative time-lapse images andquantification of HB9::GFP axongrowthwhen coculturedwith PR50
miR126
myocytes (top) or PR50
miR142myocytes (bottom). PR50
miR126myocytes in the distal compartment enhanced the axonal traversal of the distal compartment comparedwith PR50
miR142myocytes. The data
are shownas themean rate of axons that traversed the distal compartment out of the total number of axons in each field SEM (Student’s t test,n 3, ***p 0.0039). F, Representativemyocyte
contraction plot showing the bursting contractile behavior of innervated myocytes in vitro. G, Quantification of the percentage of innervated myocytes that contract in a bursting pattern shows a
diminished rate of bursting behavior in SOD1G93Amyocytes compared with LM controls. SOD1miR126 myocytes show an increase in the rate of burstingmyocytes back to the LM levels. The data are
shown as the mean percentage of bursting myocytes SEM (Student’s t test, n 3, *p 0.0291, *p 0.0156, **p 0.005656). ***p 0.001.
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blasts were transfected to overexpress either miR126-5p
(SOD1miR126; PR50
miR126) or miR142 (SOD1miR142; PR50
miR142)
and were then plated in the distal compartment of the MFC.
Myoblasts were differentiated into mature myocytes while ex-
pressing the miRs for 7 d, after which HB9::GFP explants were
cultured in the proximal compartment. Once axons reached the
microgrooves, their extension toward the muscle compartment
was monitored for 16 h (Fig. 4C). Evidently, cocultures with
SOD1miR126 and PR50
miR126 myocytes retained wild-type behav-
ior and manifested a clear rescue effect on the rate of axon tra-
versal (Fig. 4D,E; the mean traversal rate of axons: SOD1miR126,
40.77  6.68%; SOD1miR142, 12  7.6%; PR50
miR126, 45.6 
9.4%; PR50miR142, 16  3.6%). Thus far, we have shown that
myocytes expressing various ALS-linkedmutations facilitateMN
axon degeneration and delay their growth in a simplified com-
partmental coculture assay. However, while observing the cocul-
tures for longer periods, we found that axons eventually do
traverse the muscle compartment and form functional synapses
with the myocytes. Using an image-based method that we re-
cently developed to quantify contraction and assess the innerva-
tion in in vitro cocultures (Ionescu et al., 2016; Zahavi et al.,
2017), we observed that the contractile behavior of innervated
SOD1G93A myocytes is significantly different from that of inner-
vated LMmyocytes, which tend to contract in a bursting pattern
(Fig. 4F,G; Movies 5, 6). Whereas 37% of innervated myocytes
contract in a bursting pattern, only 18% of the innervated
SOD1G93A myocytes contract in this pattern (the mean rate of
bursting innervated myocytes: LM, 37.23  2.8%; SOD1G93A,
18.5 2.03%). Strikingly, SOD1miR126 myocytes retain the same
rate of bursting myocytes as the LMmyocytes (Fig. 4G; the mean
rate of bursting innervated myocytes: SOD1miR126, 37.66 
4.29%; SOD1miR142, 26.26  0.59%). Hence, miR126-5p is an
effective regulator of muscle-secreted factors, such as Sema3, and
can rescue the detrimental effect of destabilizing factors on MN
axons, as well as on NMJ function and maintenance in vitro.
miR126-5p transiently rescues early motor phenotypes of
SOD1G93A mice in vivo
NMJ disruption, muscle morphology abnormalities, and hindlimb
misprints aremajor phenotypes in SOD1G93Amice (Gurney et al.,
1994). To determine whether miR126-5p can moderate those
phenotypes, we injected SOD1G93A mice with either pLL-eGFP-
miR126 (SOD1miR126) or pLL-eGFP-miR142 (SOD1miR142) into
the right and left GC muscles of presymptomatic mice (P60),
respectively (Fig. 5A). Virus expression was validated both in
vitro on MNs and in muscle cultures (Fig. 5-1A, available at
https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f5-1) as well
as in vivo at the transcript and protein levels (Fig. 5-1B,C, avail-
able at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f5-1).
Importantly, we observed a decrease in the number of NMJs
expressing Sema3A in the pLL-eGFP-miR126-5p-injected GC
muscles in comparison with the miR142 group, suggesting that
miR-126–5p is active in the injected tissue (Fig. 5-1D, available at
https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f5-1). Next,
we performed a series of histological analyses, followed by motor
behavioral tests at two time points after injection: at the age at
which mice typically begin exhibiting ALS phenotypes (P90) as
well as in the disease end stage (P120) (Fischer et al., 2004). Be-
cause NMJ disruption is a key process in ALS, we sought to de-
termine whether overexpression ofmiR126-5p results in reduced
NMJ disruption. Briefly, both the left and right GCmuscles were
fixed and stained for synaptic markers of the NMJ (Fig. 5B).
Quantifying the percentage of intact NMJs at P90 injected mice
revealed a significantly higher innervation rate in miR126-5p-
expressing muscles compared with both mock-treated and
SOD1G93Amuscles (Fig. 5C; P90: WT, 71.58 3.32%; SODG93A,
42.58  2.64%; SOD1miR126, 64.25  5.8%; SOD1miR142,
46.54  7.2%). Furthermore, careful analysis at P120 also iden-
tified a mild rescue by miR-126–5p overexpression. (Fig. 5C;
P120: WT, 74.35  4.74%; SODG93A, 20.12  5.01%;
SOD1miR126, 30.82 3.97%; SOD1miR142, 18.18 3.12%).Next,
we performed histological analyses to determine muscle fiber
wasting and tissue abnormalities (Fig. 5D,E). P120 GC muscles
of WT, SOD1G93A, and both SOD1miR126 and SOD1miR142 were
stained with H&E for histological examination, and the minimal
diameter ofmyofibers was analyzed as described inMaterials and
Methods. We observed a mild, but significant, increase in the
minimal fiber size of the SOD1miR126-injected muscle compared
with the SOD1miR142 mock control (Fig. 5C; P120: WT, 40.25
2.28%; SODG93A, 18.5  0.64%; SOD1miR126, 23  1.87;
SOD1miR142, 19  1.47). Last, we performed a behavioral test
using the CatWalk gait analysis technique. This video-based
method is a computerized version of the ink bath assay and pro-
vides an objective and dynamic wide range of gait analyses (Deu-
mens et al., 2007). Moreover, it has been used before specifically
with the SOD1G93Amousemodel and displayed significant differ-
ences in several parameters (Mead et al., 2011; Gerber et al., 2012)
(Fig. 5F). One output is the Mean Stand Index (MSI), which
measures the speed at which the paws detach from the walking
surface. Because aged SOD1G93A mice suffer motor defects, their
MSI values for both hindlimbs are dramatically lower than their
LM values. Remarkably, the MSI values of the SOD1miR126-
injected limbs were significantly higher at P90 and similar to the
LM control values, whereas the SOD1miR142-injected limb was
reminiscent of typical SOD1G93A behavior (Fig. 5G; mean fold
change over WT: SOD1G93A, 0.68  0.02; SOD1miR126, 0.74 
0.06; SOD1miR142, 0.65 0.04; LM, 1 0.04).We also examined
other established parameters that have been shown to be altered
in the SODG93A model (Mead et al., 2011). We specifically fo-
cused on the percentage of single-support parameter, which in-
dicates the relative duration of contact of all combined paws with
the glass floor, and on the base of support parameter, which
indicates the averagewidth of limb spreading between both front,
or both hindpaws. Remarkably, we observed a significant rescue
phenotype for both parameters in the injectedmice at age of P90.
Movie 5. Myocyte exhibiting bursting contracted behavior. Time-
lapse image series of innervated SOD G93A expressing miR126-5p myo-
cyte exhibiting bursting contracted behavior. Scale bar, 25m.
Movie 6. Myocyte exhibiting nonbursting contracted behavior.
Time-lapse image series of innervated SOD G93A expressing miR142
myocyte exhibiting nonbursting behavior. Scale bar, 25m.
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Figure 5. pLL-eGFP-miR126-5p injected into GC muscles of presymptomatic SOD1G93A mice transiently rescues the early phenotype appearance in vivo. A, Schematic view of the in vivo
experimental procedure. SOD1G93Amicewere injectedwith either pLL-eGFP-miR126-5p or pLL-eGFP-miR142 in their right or left GCmuscles, respectively. Viral infectionwas validated (Figure 5-1,
available at https://doi.org/10.1523/JNEUROSCI.3037-17.2018.f5-1). B, Representative whole-mount NMJ immunostaining ofP90 SOD1G93A GC muscles injected with either miR126-5p or
miR142 lenti vectors. Red represents BTX. Green represents NFH	 synaptophysin in presynaptic neurons. Scale bar, 20m. C, The percentage of innervated NMJs in miR126-5p-injectedmuscles
is higher comparedwith its controls in both P90 and P120 (P90: Student’s t test, n 6, *p 0.0475, **p 0.001245; P120: Student’s t test, n 5, *p 0.043, **p 0.0096).D, Representative
histological images of P120 WT, SOD1G93A, miR126-5p, and miR142 GC muscle cross sections after H&E staining. Scale bar, 100m. E, Semiquantification of a GC cross section from D shows a
significant increase in the minimal muscle fiber diameter of muscles that were injected with miR126-5p (P120: Student’s t test, n 4, *p 0.031). F, Illustration of the CatWalk XT gait analysis
system that monitors mouse footprints. G, Gait analysis MSI parameter indicates the speed at which the paw loses contact with the surface. The MSI for the P90 miR126-5p-injected limbs was
significantly higher than for miR142-injected limbs (Student’s t test, *p 0.0355). H, Gait analysis percentage single-support parameter indicates the relative duration of contact of a single paw
on the glass floor. The percentage in which the injected animals were used along the run with a single pawwas significantly higher compared with SOD1G93Amice and showed similarity to theWT
control (Student’s t test, SOD1G93A-injected, ***p 0.0004; WT-SOD1G93A, ***p 0.000003). I, Gait analysis base of support parameter indicates the average width between the hindpaws. The
base of support of both P90- and P120-injectedmicewas significant higher comparedwith SOD1G93A (Student’s t test, P90 SOD1G93A-injected, ***p 0.0000006;WT-SOD1G93A, ***p 0.000007;
P120 SOD1G93A-injected, ***p 0. 0.00003; WT-SOD1G93A, ***p 0.000000009).
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Furthermore, the improvement in base of support parameter
persisted also in P120 (Fig. 5H, I; Percentage of Support Single:
SOD1G93A, 0.43 0.05; injected, 1.06 0.24; LM, 1 0.1; Base of
Support, P90: SOD1G93A, 0.87 0.01; injected, 1.02 0.02; LM,
1  0.02; P120: SOD1G93A, 0.858  0.02; injected, 0.95  0.02;
LM, 1 0.02).
Together, we demonstrated in vivo that miR126-5p reduces
the detrimental effects of muscle-secreted destabilizing fac-
tors, such as Sema3A, on MN axons and motor function in
ALS models.
Discussion
In this work, we demonstrated that the muscle toxicity in ALS is
mediated by miR126-5p. We provided one specific mechanism
for a well-described molecule (Sema3A), by which miR126-5p
contributes to ALS pathology. We have also demonstrated that
miR126-5p alterations facilitate axon degeneration andNMJ dis-
ruption in an ALS model as an outcome of presymptomatic ele-
vations in the production and secretion of their target genes,
which encode for destabilizing factors, such as Sema3 family
members. Overexpressing miR126-5p in SOD1G93A muscles in-
hibits the neurodegenerative process. These findings reveal how
alterations in miR126-5p can be toxic to MNs, and identify a non–
cell-autonomous neurodegeneration process in ALS (Fig. 6).
miR126-5p as a master regulator of proper NMJ function
Our results indicate that the expression of ALS-causative muta-
tions results in the secretion of repellent factors, including a
number of Type 3 Semaphorins and potentially other factors. It is
thus likely that a general gene repression mechanism, specifically
miR system, is altered under such conditions. This assumption is
also consistent with the fact that miR alterations are apparent in
various neurodegenerative diseases, including ALS (Haramati et
al., 2010). Here we identified such anmiR and showed how alter-
ations in this specific miR can regulate the
essential signaling pathways in MNs and
can trigger neurodegeneration. Intrigu-
ingly, and in line with our findings, a very
recent paper demonstrated a mechanism
by which miR126-5p modulates Sema3A
expression through SetD5 expression, and
it emphasizes its positive effect on retinal
endothelial cells’ survival (Villain et al.,
2018). However, aside from targeting
Sema3A and Sema3B, as well as NRP1 and
NRP2, miR126-5p is predicted to regulate
other Semaphorin signaling factors, such
as Sema6D, PLXNA2, JNK2, JNK3, and
PTEN. In addition, miR126-5p can regu-
late the ALS andmotor-unit-related genes
VEGF-A, SPAST, MMPs (Kaplan et al.,
2014), AGRIN (Vilmont et al., 2016), and
C9orf72, which are directly involved in
ALS. Therefore, miR126-5p can serve as a
master regulator ofNMJ health bycontrol-
lingmultiple signaling pathways.
Sema3 alterations in ALS: settling the
contradictory reports
A critical initiating event for the mecha-
nism outlined above is the alterations in
Sema3 signaling in ALS models and pa-
tients. Sema3 family members were previ-
ously found to be upregulated in terminal
Schwann cells in the NMJs of SOD1G93A mice (De Winter et al.,
2006). Recently, Sema3A was also shown to be elevated in the
motor cortex of postmortem ALS patients but not in their SC
(Ko¨rner et al., 2016). Consistent with this, NRP1 antibodies,
blocking the obligatory binding receptor for Sema3A, were in-
jected into SOD1G93A mice as a potential treatment (Venkova et
al., 2014). However, anti-NRP1 blocking antibody had only a
modest effect.Moreover, a recent study demonstrated that cross-
ing mice expressing a truncated form of Sema3A with SOD1G93A
mice did not result in any rescue effect (Moloney et al., 2017). An
explanation for a minor effect or not at all, as a result of blocking
Sema3A activity, could be based on the idea of multiple toxic
factors that play a role in ALS pathology. Another explanation for
this contradiction could be the fact that Sema3A plays a more
complex role in the biology of MNs. Indeed, Sema3A was shown
to increase survival when added to mass cultures of mouse MNs
(Molofsky et al., 2014) and human MNs (Birger et al., 2018).
Consistent with this, deletion of the Sema3A gene specifically in
spinal astrocytes resulted in a gradual loss of spinal MNs
(Molofsky et al., 2014), thus suggesting that Sema3A has a posi-
tive effect when introduced near the cell body. When these find-
ings are together with our results, apparently Sema3A has both
positive and negative effects on MNs, perhaps depending on its
specific subcellular localization. When Sema3A is secreted from
muscles and targets distal axons at NMJs, it mediates their desta-
bilization; however, when it is secreted by spinal astrocytes and
targets MN soma, it acts as a survival factor. Thus, it is perhaps
not surprising that a genetic approach to inhibit Sema3A in all
cells in a mouse model of ALS had no effect in inhibiting the
symptoms. The injection of anti-NRP1may have been a bit more
beneficial possibly either because it was able to inhibit Sema3A
outside the CNSmore effectively, or alternatively, because NRP1
blocks other Type 3 Semaphorins as well.
Figure 6. Alterations in Semaphorin3A regulation by miR126-5p trigger MN degeneration in ALS. miR126-5p is a negative
regulator of Sema3 signaling in skeletal muscles. Downregulation of miR126-5p in ALS disease drives the overexpression and
secretion of Sema3A and potentially other NMJ-destabilizing factors in skeletal muscles. The downregulation in miR126-5p in
diseasedMNs drives the overexpression of NRP1 specifically in axons. The excess binding and activation of the NRP1 receptor by its
overexpressed ligand Sema3A as a result of miR126-5p alteration promote NMJ disruption and axon degeneration in a spatially
confined process.
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Autonomous versus non–cell-autonomous contributions to
ALS progression
ALS is considered a complex disease, with uniqueMN features as
well as non–cell-autonomous contributions (Ilieva et al., 2009;
Musaro`, 2013). Some evidence suggests that the NMJ is the first
compartment to be disrupted in ALS rather than the MN soma;
the disease is recognized as distal axonopathy in a non–cell-
autonomous process (Fischer et al., 2004; Moloney et al., 2014).
Twomain cell populations that have been shown to play a role in
distal axonopathy are glia and muscle cells, which secrete factors
that influence MN survival and health (Moloney et al., 2014;
Tsitkanou et al., 2016). However, the complexity of the disease
and the involvement of several tissues raise controversies regard-
ing the contribution of each tissue to the disease pathology.With
skeletal muscle, few works have concluded that muscles do not
play a role in ALS pathology. Reducing hSODG93A levels by in-
jecting siRNA against its transcript directly into muscles of the
SODG93Amousemodel, as well as crossing Lox SODG37Rwith the
Cre coding sequence under the control of the muscle creatine
kinase promoter, or performing manipulations using Follistatin
did not affect the disease onset and survival (Miller et al., 2006).
In vitro application of muscle-CM from SODG93A-expressing
muscle on healthymass culture and ES cell-derivedMNs resulted
in no effect (Nagai et al., 2007). However, in contrast with these
findings, evidence indicates that overexpressing mutant SOD1
protein specifically in healthy skeletal muscle induces an ALS
phenotype and the degeneration ofMNs, supporting a direct role
for muscle in ALS physiology (Dobrowolny et al., 2008; Wong
and Martin, 2010). Moreover, muscle from ALS patients and
models has been shown to exhibit impaired mitochondrial func-
tion (Shi et al., 2010) and abnormalities in muscle biology
(Manzano et al., 2012). Here, we demonstrated that applying
presymptomatic SOD1G93A muscle-CM directly, and only on
SOD1G93A-expressing MN axon tips, results in their degenera-
tion, suggesting that both tissue types are necessary for exhibiting
the disease phenotype. Furthermore, contradictory reports were
published on transgenic mice expressing SOD1G93A only in the
MNs. For example, Lino et al. (2002) showed a very mild pheno-
type, whereas Jaarsma et al. (2008) demonstrated a significant
toxic effect. In this study, we showed thatmuscle-secreted factors
are capable ofmodulatingMNaxons.Whereaswild-typemuscle-
secreted factors facilitate axon growth, several ALS-relatedmuta-
tions, expressed in muscles, result in the secretion of factors that
cause retraction and degeneration when exclusively introduced
to axons. At least one of these factors is Sema3A. The secretion of
Sema3A by the muscle itself is likely to contribute to the instabil-
ity of the MN axons. However, our results also show that ALS
mutant muscles themselves cause axon degeneration and a delay
in axon growth toward the muscles, but eventually the connec-
tions between axons andmuscles are established. Thus, at least in
our system, apparently the non–cell-autonomous contributions
of themuscle are insufficient to recapitulate all the toxic effects on
MNs. However, once theMNs also carry an ALSmutation, axons
are more susceptible to degeneration by mutated muscle-CM
(Fig. 3G,H), thus demonstrating the critical contribution of the
MNs to ALS progression.
Do diseased muscles initiate axon degeneration or
inhibit regeneration?
Our data suggest that muscles are involved in modulating MN
health in ALS disease. We showed, both in vivo and in vitro, that
muscles secrete destabilizing factors, such as Sema3A, as well as
facilitate axon degeneration and NMJ disruption. Intriguingly, a
previous study demonstrated that Sema3A expression is limited
only to myosin IIb positive fibers, which are prone to be dis-
rupted first in ALS (De Winter et al., 2006). These data support
our findings in which the percentage of NMJs that express
Sema3A andNRP1 is reduced at the end stage of the disease,most
likely along with the fast fatigue NMJs. However, although the
suggested mechanism involves muscle-MN interaction, because
of the nature of our experimental model, we cannot fully deter-
mine whether the mutated muscles act by initiating the degener-
ation of MN axons or by inhibiting their regrowth and NMJ
repair, which was also suggested previously (Arbour et al., 2015).
Perhaps muscle toxicity plays an active role in both pathways.
However, future efforts should be made to resolve this issue.
miRs as a potential therapeutic strategy for ALS disease
In this paper, we demonstrated a positive effect of miR126-5p on
ALS disease progression and suggested a potential therapeutic
strategy for ALS disease. Nevertheless, our in vivo data show that
the most significant positive effect of miR126-5p on ALS pathol-
ogy was achieved at P90, whereas at later stages only modest
effects were achieved. These results point to miR126-5p as a tar-
geted treatment for an early phenotype but without a sustained
beneficial contribution at later stages of ALS disease. However,
keeping in mind that we injected miR126-5p into small parts of
the whole GCmuscle and only once at P60, as well as the fact that
the efficiency of the procedure of the injection can also affect the
efficacy of this treatment, we cannot rule out the possibility that a
broader test of long-term efficacy will result in a stronger and
more positive outcome. An alternative future study should ad-
dress this issue by crossing a conditional tissue-specific knock-
out of miR126-5p mice with SOD1G93A.
Considering that ALS is amultifactorial disease, and thatmiRs
are predicted to regulate a wide range of metabolic and signaling
pathways, manipulating their subcellular levels in neurons, mus-
cles, or glia, miRs should generally be explored as a potential
therapeutic strategy or tool for treatment of ALS and possibly
other neurodegenerative diseases.
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